Steven James, MS
Steven James has over 35 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Mr. James was most recently president, Chief Executive Officer and director of Pionyr Immunotherapeutics until it was acquired by Ikena Oncology. Previously, he was president, Chief Executive Officer and director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president, Chief Executive Officer and director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Mr. James is currently a director of Allakos Inc. Ventus Therapeutics and Lyterian Therapeutics. He was formerly the chairman of Antiva Biosciences, and a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).
Learn more about Steven
LinkedIn
Juvena’s CSO, Dr. O’Connell, was an invited speaker at the 6th Annual Fibrotic Drug Discovery Summit in Nov. 2022 and discussed how decoding stem cell secreted proteins can enable drug discovery for fibrotic degenerative diseases, providing an overview of Juvena’s pulmonary and hepatic programs.
Annual BioFuture 2022 Event Recognizes Juvena CEO Dr. Hanadie Yousef Among Longevity Pioneers Shaping Expectations in Healthcare and Celebrates the Company’s Series A Announcement
Annual BioFuture 2022 Event Recognizes Juvena CEO Dr. Hanadie Yousef Among Longevity Pioneers Shaping Expectations in Healthcare and Celebrates the Company’s Series A Announcement
Juvena Therapeutics is recognized for its transformative science that targets unmet medical needs as well as for the quality of its management team as part of the Emerging Company Showcase at the prestigious Life Sciences Summit.
Andrew Campbell
Andrew Campbell has 35 years of multi-disciplinary pharmaceutical Quality Assurance experience in both development and commercial stage companies. He has broad experience with parenteral, tablet, and suspension dosage forms. He has assisted several clinical-stage companies through the development cycle, culminating in successful regulatory filings, regulatory inspections, and marketing authorizations.
He has extensive experience with design, remediation, and implementation of Quality Systems. He is an accomplished trainer, speaking to industry groups on the topics of Supplier Management, Auditing, Investigations, and Change Management.
Andrew obtained his Bachelor’s degree in Chemistry from UC Davis.
Learn more about Andrew
LinkedIn
Sharon Louie, PhD
Sharon joined Juvena Therapeutics as a Senior Scientist working on preclinical in vivo disease modeling and drug discovery. She received her B.S. in Molecular Toxicology and Ph.D in Metabolic Biology from UC Berkeley where she used chemoproteomic and metabolomic technologies to uncover metabolic drivers of triple-negative breast cancers. Sharon completed her post-doctoral training at Boston Children’s Hospital/Harvard Medical School where she developed a transplantation assay for lung stem cell-derived organoids to mouse models with lung disorders to assess the potential for future cell therapies. She then spent a few years in the biotech industry leading studies to support preclinical drug development.
Sharon has been awarded multiple fellowships during her time in academia, including the NSF graduate fellowship and the Hope Funds for Cancer fellowship. She is a co-author on 22 publications.
Learn more about Sharon
LinkedIn
BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.
Vengadeshprabhu Karuppa gounder, PhD
Dr. Vengadeshprabhu Karuppa gounder, PhD, joined Juvena Therapeutics as a Scientist II working on preclinical in vivo disease modeling and drug discovery. Dr. Karuppa gounder brings over 10 years of pharmacology & drug development experience in academic research. Dr. Karuppa gounder has strong background in pharmacology, immunology and molecular biology. He has several years of experience developing preclinical animal models in areas of diabetes, NASH, cardiomyopathy, autoimmune diseases, aging, osteoarthritis, IBD, renal and inflammatory diseases.
Dr. Karuppa gounder completed his Undergraduate and Master’s work on Pharmaceutical Sciences at the TamilNadu DR. MGR Medical University, Chennai, India and did his Ph.D. studies at Niigata University of Pharmacy and Applied Life Sciences, Japan, where he studied the role of HMGB1 and GPCR role in diabetes and autoimmune disease models. Then he joined as a postdoctoral researcher at Penn State College of Medicine, PA. During his fellowship, Dr. Karuppa gounder established new methods to study the role of GPCR signaling in synovitis, osteoarthritis and osteoporosis in mouse models and treatment options.
Dr. Karuppa gounder achieved the first author in leading scientific journals, Science Translational Medicine, & Aging Research Reviews and co-author of several research and review articles, and bagged several awards and grants.
Learn more about Vengadeshprabhu
